Relevant bibliographies by topics / Targeted Drug Regimens

Contents

  1. Journal articles
  2. Books
  3. Book chapters
  4. Conference papers
  5. Reports

Academic literature on the topic 'Targeted Drug Regimens'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Targeted Drug Regimens.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Targeted Drug Regimens"

1

NIYOZOVA, Shakhnoza, and Sergey KAMISHOV. "TARGETED THERAPY IN THE TREATMENT OF PATIENTS METASTATIC COLORECTAL CANCER." Journal of biomedicine and practice 7, no. 4 (2022): 6. https://doi.org/10.5281/zenodo.7027285.

Full text
Abstract:
Objective: to study the possibilities of targeted therapy in patients with metastatic colorectal cancer (CRC). Methods: three groups of 75 CRC patients with liver metastases received standard chemotherapy regimens (CT) XELOX and FOLFOX4; in the experimental groups, the treatment regimens included targeted drugs bevacizumab and cetuximab. Results: the addition of targeted drugs to the treatment regimens for patients with metastatic CRC significantly increased both the overall survival of patients and increased the time for the appearance of signs of disease progression. The median follow-up was
APA, Harvard, Vancouver, ISO, and other styles
2

Mehta, Sandhya, Jinlin Song, Melissa Pavilack, et al. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, no. 29_suppl (2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.

Full text
Abstract:
282 Background: HER2-positive (+) metastatic breast cancer (mBC) has a poor prognosis and many patients require multiple lines of HER2 targeted regimens. This study aims to examine the treatment sequencing of anti-HER2 regimens for HER2+ mBC among Medicare beneficiaries. Methods: A retrospective study was conducted using linked 1999-2016 Surveillance, Epidemiology, and End Results (SEER) cancer registries and Medicare claims. Adults patients who had mBC diagnosis, HER2+ status documented in SEER or claims of ≥1 anti-HER2 drug, continuous enrollment in Medicare from the date of mBC diagnosis un
APA, Harvard, Vancouver, ISO, and other styles
3

Levêque, Dominique. "Improving the Dosing Schedules of Targeted Anticancer Agents." Pharmaceuticals 18, no. 6 (2025): 848. https://doi.org/10.3390/ph18060848.

Full text
Abstract:
Beyond developing new agents, cancer treatment can also be optimized by modifying the dosing regimen of approved drugs. Academic teams have experimented with different ways of improving drug regimens, leading to off-label practices for therapeutic and/or economic purposes, and currently, drug regulatory agencies have begun to reappraise this often-neglected topic. This concept also considers the patient’s perspective in terms of quality of life and convenience, including the concept of time toxicity. Overall, the optimization of drug dosing of anticancer agents may be viewed on three sides: th
APA, Harvard, Vancouver, ISO, and other styles
4

Luchinin, E. A., M. V. Zhuravleva, T. V. Shelekhova, V. S. Bogova, and E. V. Luchinina. "Application of the cost-effectiveness method in improving the pharmacotherapy of multiple myeloma." Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, no. 1 (April 19, 2023): 15–25. http://dx.doi.org/10.37489/2588-0519-2023-1-15-25.

Full text
Abstract:
Multiple myeloma (MM) accounts for 1 % of all cancers and about 10 % of all hemoblastoses. The use of innovative technologies with the inclusion of targeted drugs leads to a significant improvement in the quality of pharmacotherapy and the achievement of overall survival (OS).The aim of the work is to conduct a pharmacoeconomic analysis of the most used MM therapy regimens with the use of targeted drugs and to determine the dominant treatment regimens using a costeffectiveness analysis.Materials and methods. To determine the cost of a course of treatment, we summed up the costs of drugs includ
APA, Harvard, Vancouver, ISO, and other styles
5

Ayupov, R. T., A. A. Izmailov, K. V. Menshikov, et al. "Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCURency." Meditsinskiy sovet = Medical Council, no. 20 (December 9, 2021): 47–52. http://dx.doi.org/10.21518/2079-701x-2021-20-47-52.

Full text
Abstract:
Colon cancer therapy currently includes at least 3 cytostatic agents and 6 targeted drugs, combinations of which constitute many different treatment regimens. Nevertheless, as shown by various clinical studies, the use of oxaliplatin, irinotecan and fluoropyrimidine regimens in conjunction with monoclonal targeted drugs remains the main one. After progression on the main lines of therapy and registration of refractory disease, there are not many standard options for treatment in the 3rd line that have statistical confidence in terms of improving survival rates. There have been attempts to sear
APA, Harvard, Vancouver, ISO, and other styles
6

Chaudhuri, Aiswarya, Dulla Naveen Kumar, Deepa Dehari, et al. "Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)." Pharmaceuticals 15, no. 5 (2022): 542. http://dx.doi.org/10.3390/ph15050542.

Full text
Abstract:
Triple-negative breast cancer (TNBC) is considered one of the un-manageable types of breast cancer, involving devoid of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER 2) receptors. Due to their ability of recurrence and metastasis, the management of TNBC remains a mainstay challenge, despite the advancements in cancer therapies. Conventional chemotherapy remains the only treatment regimen against TNBC and suffers several limitations such as low bioavailability, systemic toxicity, less targetability, and multi-drug resistance. Although various targeted therapies have
APA, Harvard, Vancouver, ISO, and other styles
7

Bolotina, L. V., and A. D. Kaprin. "Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices." Medical Council, no. 19 (November 11, 2018): 22–26. http://dx.doi.org/10.21518/2079-701x-2018-19-22-26.

Full text
Abstract:
The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, afliberc
APA, Harvard, Vancouver, ISO, and other styles
8

Liu, Xiyan. "Research on the Treatment of Neuro - Oncological Tumors with Targeted Drugs." Theoretical and Natural Science 113, no. 1 (2025): 49–54. https://doi.org/10.54254/2753-8818/2025.au24098.

Full text
Abstract:
Gliomas have a relatively high incidence and a remarkable degree of malignancy. Traditional treatment methods often have adverse effects on the central nervous system during their application. Targeted drugs, as a cutting - edge treatment approach, can precisely act on specific targets of tumor cells and imped the growth, proliferation, survival, and metastasis processes of tumor cells. This article elaborates on the classification of neuro - oncological tumors and targeted drugs and deeply analyzes the mechanism of targeted drugs in the treatment of neuro - oncological tumors from aspects suc
APA, Harvard, Vancouver, ISO, and other styles
9

Kendall, Emily A., Shelly Malhotra, Sarah Cook-Scalise, David W. Dowdy, and Claudia M. Denkinger. "Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model." Clinical Infectious Diseases 71, no. 11 (2019): 2889–96. http://dx.doi.org/10.1093/cid/ciz1179.

Full text
Abstract:
Abstract Background To appropriately treat tuberculosis (TB) with regimens that combine novel and older drugs, evidence-based, context-specific strategies for drug-susceptibility testing (DST) will be required. Methods We created a Markov state-transition model of 100 000 adults with TB receiving a novel, fluoroquinolone (FQ)–containing regimen. We estimated clinical outcomes and resource utilization with no FQ-DST, universal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB (“targeted FQ-DST”). We considered scenarios of stronger (South Africa) and weaker (Southeast Asia) correla
APA, Harvard, Vancouver, ISO, and other styles
10

Qu, Hongchen, Zhongyi Mu, Kai Wang, and Bin Hu. "A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma." Journal of Oncology 2022 (March 28, 2022): 1–8. http://dx.doi.org/10.1155/2022/5805289.

Full text
Abstract:
Objective. Nivolumab plus other drugs have provided significant benefits in patients with metastatic renal cell carcinoma (mRCC), but most of the available comparisons were conducted with sunitinib, and differences in efficacy with targeted drugs were marginally reported. Thus, this study used a network meta-analysis to compare the difference in efficacy between nivolumab combination therapy and other targeted agents. Methods. In this systematic review and network meta-analysis, we searched PubMed, Embase, and Cochrane Library databases for randomized controlled trials (RCTs) with the time set
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Targeted Drug Regimens"

1

Calabrò, Fabio, and Cora N. Sternberg. Treatment of metastatic bladder cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Full text
Abstract:
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led
APA, Harvard, Vancouver, ISO, and other styles
2

Kramer, Carolyn, and Emily Blumberg. Immunosuppressants and Antiretroviral Therapy in HIV-Positive Transplant Patients. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190493097.003.0028.

Full text
Abstract:
Protease inhibitors (PIs), especially ritonavir, are inhibitors of CYP3A4 and P-gp1 and can significantly increase levels of calcineurin inhibitors and mammalian target of rapamycin (mTOR) inhibitors. Cobicistat is an inhibitor of CYP3A4, and its effect on levels of calcineurin inhibitors and mTOR inhibitors is likely to be similar to that of ritonavir. Efavirenz may result in lower concentrations of calcineurin inhibitors and mTOR inhibitors. Dose reduction and careful attention to monitoring drug levels are critical to avoid toxicity and maintain therapeutic immunosuppressive concentrations
APA, Harvard, Vancouver, ISO, and other styles
3

Fragoulis, George E., and Iain B. McInnes. Small molecules in the treatment of psoriatic arthritis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0031.

Full text
Abstract:
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis, occurring in about one third of psoriasis patients, and exhibiting very varied clinical manifestations and comorbidities. Although the clinical outcome of the disease has been significantly improved recently, mainly due to utilization of novel agents targeting the IL-23/-17 axis, unmet needs still exist. Emerging insights into the disease’s pathogenesis led to development of new drugs acting against critical molecular targets and their efficacy in psoriasis and/or PsA has been tested in Phase III clinical trials. Some of these ther
APA, Harvard, Vancouver, ISO, and other styles
4

Paterson, David L., and Yoshiro Hayashi. Antimicrobial selection policies in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0286.

Full text
Abstract:
Antibiotic selection is a crucial drug choice in critically-ill patients. Optimization of empiric antibiotic choice can be gained by knowledge of the site of infection and the probable causative organisms at that site. This should be linked with knowledge of the local epidemiology of antibiotic resistance in the actual intensive care unit housing the patient. Initial empiric antimicrobial choice may need to be broad in order to cover potential antibiotic-resistant pathogens. However, it is important to be prudent in antibiotic strategy since the selection of multiple-resistant organisms by exc
APA, Harvard, Vancouver, ISO, and other styles
5

Kuypers, Dirk R. J., and Maarten Naesens. Immunosuppression. Edited by Jeremy R. Chapman. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0281_update_001.

Full text
Abstract:
Combination immunosuppressive therapy produces excellent short-term results after kidney transplantation. Long-term graft survival has improved, but less dramatically. Death with a functioning graft remains the primary cause of graft loss. Dosing of current immunosuppressive therapy balances between careful clinical interpretation of time-driven immunological risk assessments and drug-related toxicity on the one hand, and the use of simple surrogate drug exposure indicators like blood/plasma concentrations on the other. The combined use of calcineurin-inhibitors (CNIs) with mycophenolic acids
APA, Harvard, Vancouver, ISO, and other styles
6

Masino, PHD, Susan A., ed. Ketogenic Diet and Metabolic Therapies. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190497996.001.0001.

Full text
Abstract:
Ketogenic diets have been used to treat epilepsy for nearly a century. Alongside enduring clinical success with a ketogenic diet, metabolism’s critical role in health and in diseases in the central nervous system and throughout the body is increasingly appreciated. Furthermore, metabolism-based strategies have been proven equal or even superior to pharmacological treatments in specific cases and for specific diseases. Rather than causing unwanted off-target pharmacological side effects, addressing metabolic dysfunction can improve overall health simultaneously. Enduring interest in the ketogen
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Targeted Drug Regimens"

1

Kulkarni, Harshad R. "PSMA Radioligand Therapy: A Revolution in the Precision Radiomolecular Oncology of Prostate Cancer." In Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-33533-4_18.

Full text
Abstract:
AbstractThe incidence of prostate cancer is ever increasing. After various time intervals, the disease almost always becomes resistant to the standard hormone treatment (castration-resistant prostate cancer, CRPC). Most patients with CRPC either already have metastases at diagnosis or develop them during the early months of follow-up, which is associated with a relatively poor prognosis. The taxane-based chemotherapy for metastatic CRPC (mCRPC), first line with docetaxel and second line using cabazitaxel, are associated with a high incidence of adverse effects. The novel androgen-axis drugs (N
APA, Harvard, Vancouver, ISO, and other styles
2

Zulu, Sara, and Michelle Kenyon. "Principles of Conditioning Therapy and Cell Infusion." In The European Blood and Marrow Transplantation Textbook for Nurses. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23394-4_6.

Full text
Abstract:
AbstractPrior to haematopoietic stem cell transplant (HSCT), conditioning therapy is used for disease eradication, creation of space for engraftment and immunosuppression. Conditioning therapy includes combinations of chemotherapy, radiotherapy and/or immunotherapy and can be administered in the immediate days leading up to, and sometimes the days immediately following, the cell infusion. Total body irradiation (TBI) is generally used as part of conditioning regimens preceding allogeneic HSCT and is able to target sanctuary sites where some drugs cannot reach. Cancer immunotherapy treatment ha
APA, Harvard, Vancouver, ISO, and other styles
3

Jain, Dr Tanya. "SMART PILLS AND NANOMEDICINES: THE FUTURE OF DRUG DELIVERY." In Futuristic Trends in Pharmacy & Nursing Volume 3 Book 20. Iterative International Publisher, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3bgpn20p5ch3.

Full text
Abstract:
Smart pills and nanomedicine represent cutting-edge advancements in drug delivery, offering innovative solutions to enhance therapeutic efficacy and patient outcomes. Smart pills, equipped with sensors and communication technology, enable real-time monitoring of drug release and physiological parameters, optimizing treatment regimens. Nanomedicine, utilizing nanoscale materials, provides targeted drug delivery, minimizing side effects and improving bioavailability. This review explores the synergistic potential of smart pills and nanomedicine, elucidating their role in revolutionizing healthca
APA, Harvard, Vancouver, ISO, and other styles
4

Umar Zango, Usman, Aminu Abubakar, Rohit Saxena, and Vedpriya Arya. "Phyto-nanotechnology: Enhancing Plant Based Chemical Constituent Mediated Anticancer Therapies." In Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815079784123010011.

Full text
Abstract:
95% of anti-cancer agents were associated with the worst pharmaceutical and pharmacokinetic properties including poor targeted cellular uptake, shorter half.life, toxicity, and many more. In this regard, nanotechnology including nano.medicines, nano-carriers, and nanomaterials may emerge as a beneficial tool to facilitate an efficient delivery of therapeutic regimens by adapting active or passive targeting mechanisms. The nanotechnology-based delivery system of phytoconstituents can efficiently battle against recalcitrant TNBC. This chapter highlighted the nanotechnology-based therapeutic appr
APA, Harvard, Vancouver, ISO, and other styles
5

Usha Devi Aiswarya, Sreekumar, and Smitha V. Bava. "Unveiling the Potency of Phyto-Constituents to Target TNBC: Mechanism to Therapeutics." In Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815079784123010010.

Full text
Abstract:
The development of an effective therapeutic approach against TNBC is a formidable challenge at present. Efficacy and drug resistance issues in response to adjuvant and neoadjuvant chemotherapy have prompted the development of new therapeutic regimens. In this concern, the scientific community has started exploring natural sources including medicinal plants exhibiting anti-cancer activity for their potent inhibitory potential against TNBC. The comprehensive analysis underlying the molecular mechanism of action of these natural bio-compounds provided substantial evidence to subject a few of thes
APA, Harvard, Vancouver, ISO, and other styles
6

Barkat, Harshita Abul, Md Abul Barkat, Mohamad Taleuzzaman, Sabya Sachi Das, Md Rizwanullah, and Hazrina Ab Hadi. "Receptor-Based Combinatorial Nanomedicines." In Handbook of Research on Advancements in Cancer Therapeutics. IGI Global, 2021. http://dx.doi.org/10.4018/978-1-7998-6530-8.ch011.

Full text
Abstract:
Nanotechnology-based drug-delivery systems, as an anticancer therapy tool, have shown significant potentials for the diagnosis and treatment of cancer. Recent studies have demonstrated that cancer therapy could be efficiently achieved by combinatorial therapies, approaches using multiple drug regimens for targeting cancers. However, their usages have been limited due to shorter half-lives of chemotherapeutic agents, insignificant targetability to tumor sites and suboptimal levels of co-administered conventional drug moieties. Thus, nanotechnology-based drug-delivery systems with effective targ
APA, Harvard, Vancouver, ISO, and other styles
7

Padma, K. R., K. R. Don, and P. Josthna. "Understanding the Mechanism of Targeted Therapy- The Next Generation for Cancer Treatment." In Promising Cancer Therapeutic Drug Targets: Recent Advancements. BENTHAM SCIENCE PUBLISHERS, 2025. https://doi.org/10.2174/9789815238570125010013.

Full text
Abstract:
In recent years, there has been significant progress in understanding the cellular, molecular, and systemic factors that contribute to the development and spread of cancer. This has been made possible by advancements in sequencing methods and data analysis, which have allowed for the identification of various genomic alterations in tumors. While there are currently several specific therapies available, there is a growing focus on target-specific treatments that show better results in cancer treatment. Cancer is widely recognized as the second deadliest disease in the world. For many years, the
APA, Harvard, Vancouver, ISO, and other styles
8

Sahoo, Prakash Kumar. "SMART NANOMATERIALS IN DRUG DELIVERY SYSTEM." In Futuristic Trends in Chemical Material Sciences & Nano Technology Volume 3 Book 2. Iterative International Publishers, Selfypage Developers Pvt Ltd, 2024. http://dx.doi.org/10.58532/v3becm2ch19.

Full text
Abstract:
The field of drug delivery has witnessed a paradigm shift with the advent of smart nanomaterials. These advanced materials, designed at the nanoscale, offer unprecedented control over drug release, targeting, and therapeutic efficacy. This abstract provides an overview of the transformative potential of smart nanomaterials in drug delivery systems. Smart nanomaterials are engineered to respond to specific stimuli, such as changes in pH, temperature, or enzymatic activity, allowing for precise and controlled drug release at the desired site of action. This targeted drug delivery minimizes off-t
APA, Harvard, Vancouver, ISO, and other styles
9

Regan Kelly, Raje Satyajeet, Saravanamuthu Cartik, and Payne Philip R.O. "Conceptual Knowledge Discovery in Databases for Drug Combinations Predictions in Malignant Melanoma." In Studies in Health Technology and Informatics. IOS Press, 2015. https://doi.org/10.3233/978-1-61499-564-7-663.

Full text
Abstract:
The worldwide incidence of melanoma is rising faster than any other cancer, and prognosis for patients with metastatic disease is poor. Current targeted therapies are limited in their durability and/or effect size in certain patient populations due to acquired mechanisms of resistance. Thus, the development of synergistic combinatorial treatment regimens holds great promise to improve patient outcomes. We have previously shown that a model for in-silico knowledge discovery, Translational Ontology-anchored Knowledge Discovery Engine (TOKEn), is able to generate valid relationships between bimol
APA, Harvard, Vancouver, ISO, and other styles
10

Thanawiroon, Charuwan, and Bancha Yingngam. "Monoclonal Antibody Therapies in Cancer Immunotherapy." In Advances in Medical Diagnosis, Treatment, and Care. IGI Global, 2024. http://dx.doi.org/10.4018/979-8-3693-3976-3.ch012.

Full text
Abstract:
Monoclonal antibodies (mAbs) can significantly improve patient outcomes in cancer treatment while reducing related side effects, offering a targeted therapy alternative to traditional treatment regimens. This chapter describes the development, mechanisms, and applications of mAb therapies as critical components of cancer immunotherapy. The chapter covers the history and progression of the use of mAbs in therapy, their multiple mechanisms—such as immune checkpoint inhibitors, the acumen for cancer antigens and antibody—drug conjugates—and the newest developments in this area. Moreover, this cha
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Targeted Drug Regimens"

1

Isametov, Davran Rashitovich, Shamil Hanafievich Gantsev, Zhaksylyk Orazbaevich Maulenov, Dauranbek Tursunkulovich Arybzhanov, and Davlat Saitmuratovich Tursumetov. "RESULTS OF CHEMOINFUSION INTO A BRONCHIAL ARTERY BRANCH IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER." In Themed collection of papers from Foreign International Scientific Conference «Trends in the development of science and Global challenges» by HNRI «National development» in cooperation with AFP. June 2024. – Managua (Nicaragua). Crossref, 2024. http://dx.doi.org/10.37539/240620.2024.22.82.004.

Full text
Abstract:
Lung cancer, despite modern trends in the development of medical oncology, remains one of the key tasks of clinical medicine. On the one hand, this is due to the fact that the overwhelming number of patients at the time of initial diagnosis have an unresectable/inoperable stage of the disease, on the other hand, the latest predictive indicators in the world still indicate a high incidence of morbidity and mortality in terms of cancer incidence. In this regard, there is an urgent need to find alternative ways to treat the malignant process, including drugs. Drug therapy for lung cancer in the w
APA, Harvard, Vancouver, ISO, and other styles
2

Mansoor, H., N. Hirani, VV Chavan, et al. "Clinical utility of target-based next-generation sequencing for drug-resistant tuberculosis: a pilot from Mumbai, India." In MSF Scientific Days International 2022. MSF-USA, 2022. http://dx.doi.org/10.57740/atfq-6s03.

Full text
Abstract:
INTRODUCTION In countries with a high tuberculosis (TB) burden, poor access to drug susceptibility testing is a major bottleneck in diagnosing drug-resistant (DR) TB. India is estimated to account for a quarter of multidrug-resistant (MDR)-TB patients globally, with around 124,000 cases in 2020. Mumbai, a densely populated city in Maharashtra State, is a DR-TB hotspot with 24% of treatment- naïve cases, and 41% of previously-treated cases, having MDR-TB, and a high frequency of fluoroquinolone resistance occurring among these MDR-TB cases. Targeted next- generation sequencing (tNGS) is a promi
APA, Harvard, Vancouver, ISO, and other styles
3

Bergstrom, Donald A., Natalya Bodyak, Alex Yurkovetskiy, et al. "Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-lb-231.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Blanco, Elvin, Takafumi Sangai, Funda Meric-Bernstam, and Mauro Ferrari. "Chemotherapeutic Synergy Enhancement Through Micellar Nanotherapeutics." In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13263.

Full text
Abstract:
Current chemotherapeutic regimens involve the administration of a combination of agents with hopes of gaining synergistic cell-killing effects observed in vitro. However, drug synergy is rarely realized clinically given the different pharmacokinetic profiles of the drugs. Recent findings show that a combination of rapamycin and paclitaxel proves highly effective at hindering growth of tumors wherein the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. Our objective was to fabricate a micellar nanotherapeutic platform capable of delivering a multitude of ag
APA, Harvard, Vancouver, ISO, and other styles
5

Fernandez, Eric, Martin Robertson, Chris Snell, David A. Fell, Christophe Chassagnole, and Robert C. Jackson. "Abstract A36: An anticancer drug combination and regimen database for research and clinical optimization." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-a36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wick, Michael J., Joshua D. Cooper, Scott G. Kelly, et al. "Abstract A21: Preclinical bioanalytical development to optimize drug treatment regimens using orthotopic models of human gastric cancer." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Scheiner, Stefan, Peter Pivonka, David W. Smith, and Colin R. Dunstan. "Computer Simulation-Based Modeling of the Pharmaceutical Intervention of Postmenopausal Osteoporosis by Denosumab." In ASME 2012 11th Biennial Conference on Engineering Systems Design and Analysis. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/esda2012-82990.

Full text
Abstract:
Postmenopausal osteoporosis (PMO), leading to a higher bone fracture risk, is characterized by a significantly increasing bone porosity. Recently, denosumab, which is able to efficiently interfere with bone resorption, has been approved for the treatment of PMO. In order to optimize the design of drug administration regimes, we propose a computational methodology, based on mechanistic mathematical modeling of bone remodeling, considering the governing biochemical and biomechanical regulation mechanisms, and the targeted action of denosumab. The time-dependent serum concentration of denosumab,
APA, Harvard, Vancouver, ISO, and other styles
8

Lichtenfels, Martina, Vivian Fontana, Isis Mendes Barbosa, et al. "Intrinsic chemoresistance in luminal breast neoplasms: efficacy from an innovative in vitro chemoresistance platform." In Brazilian Breast Cancer Symposium 2024. Mastology, 2024. http://dx.doi.org/10.29289/259453942024v34s1056.

Full text
Abstract:
Objective: The aim of this study was to validate an in vitro chemoresistance platform, BioversoÒ, to predict the responsiveness of luminal tumors to cytotoxic and target therapy drugs. Methodology: Patients with estrogen receptor (ER)-positive HER2-negative breast cancer (BC) who underwent upfront surgery were included. Fresh tumor samples were collected during surgery and dissociated to obtain the tumor cells. The tumor cells were cultured in the BioversoÒ with the drugs, and after 72h, cell viability was evaluated. The test result is defined as low, medium, and high resistance. Results: Samp
APA, Harvard, Vancouver, ISO, and other styles
9

Bhoi, Suman, Mong Li Lee, Wynne Hsu, Hao Sen Andrew Fang, and Ngiap Chuan Tan. "Chronic Disease Management with Personalized Lab Test Response Prediction." In Thirty-First International Joint Conference on Artificial Intelligence {IJCAI-22}. International Joint Conferences on Artificial Intelligence Organization, 2022. http://dx.doi.org/10.24963/ijcai.2022/699.

Full text
Abstract:
Chronic disease management involves frequent administration of invasive lab procedures in order for clinicians to determine the best course of treatment regimes for these patients. However, patients are often put off by these invasive lab procedures and do not follow the appointment schedules. This has resulted in poor management of their chronic conditions leading to unnecessary disease complications. An AI system that is able to personalize the prediction of individual patient lab test responses will enable clinicians to titrate the medications to achieve the desired therapeutic outcome. Acc
APA, Harvard, Vancouver, ISO, and other styles
10

Koraćević, Goran, Slađana Mićić, and Milovan Stojanović. "Uncontrolled arterial hypertension in the mirror of ethiopathogenetic, diagnostic and clinical aspects of the disease." In 7th International Congress of Cardionephrology KARNEF 2025. Punta Niš, 2025. https://doi.org/10.46793/karnef25.301k.

Full text
Abstract:
The term uncontrolled hypertension (UH) is commonly applied to all patients with hypertension (HTA) who do not achieve their target blood pressure (BP) for various reasons, which may include pseudoresistance or resistant HTA. Resistant HTA is defined as a BP reading exceeding 140/90 mmHg in the doctor’s office in patients who are on three or more antihypertensive medications, including diuretics, at optimal or maximally tolerated doses. Pseudoresistant HTA encompasses improper BP measurement techniques, white-coat effect, drug-induced HTA, secondary HTA, and incorrectness in antihypertensive m
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Targeted Drug Regimens"

1

Jorgensen, Frieda, Andre Charlett, Craig Swift, Anais Painset, and Nicolae Corcionivoschi. A survey of the levels of Campylobacter spp. contamination and prevalence of selected antimicrobial resistance determinants in fresh whole UK-produced chilled chickens at retail sale (non-major retailers). Food Standards Agency, 2021. http://dx.doi.org/10.46756/sci.fsa.xls618.

Full text
Abstract:
Campylobacter spp. are the most common bacterial cause of foodborne illness in the UK, with chicken considered to be the most important vehicle for this organism. The UK Food Standards Agency (FSA) agreed with industry to reduce Campylobacter spp. contamination in raw chicken and issued a target to reduce the prevalence of the most contaminated chickens (those with more than 1000 cfu per g chicken neck skin) to below 10 % at the end of the slaughter process, initially by 2016. To help monitor progress, a series of UK-wide surveys were undertaken to determine the levels of Campylobacter spp. on
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Targeted Drug Regimens' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography